Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose esketamine during thoracic surgery for postoperative depressive mood and BDNF in lung cancer patients
ChiCTR2100049003Phase 4Recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of esketamine in major depressive disorder (MDD) and postoperative pain (2 arms), sponsored by The Second Xiangya Hospital. Primary endpoints: MADRS depression scale score, Plasma BDNF level and 1 more. Started Jul 2021; status: recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)postoperative pain
Beyond the preview
Go deeper on ChiCTR2100049003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049003.